Latest National Institute on Drug Abuse Stories
SOUTH SAN FRANCISCO, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction.
ST. JOSEPH, Mich., Sept.
American and Italian researchers have found that a novel drug allows anandamide â€“ a marijuana-like chemical in the body â€“ to effectively control pain at the site of an injury.
Selected awardee studies the mechanisms of latent HIV infection to develop counter measures aimed at eliminating the virus.
A regulatory protein best known for its role in a rare genetic brain disorder also may play a critical role in cocaine addiction.
SOUTH SAN FRANCISCO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc.
Discovery could lead to better ways of predicting drug abuse risk and treating addictions.
While ecstasy became infamous as a drug taken at night clubs or during parties, new research suggests that it might help those suffering from post-traumatic stress disorder (PTSD).
CORAL GABLES, Fla., April 13 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S.
Normal individuals who scored high on a measure of impulsive/antisocial traits display a hypersensitive brain reward system, according to a brain imaging study by researchers at Vanderbilt University.